Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Influenza A Virus Hemagglutinin Protein H3N2 Subtype (HA H3N2)
- Target
- HA H3N2
- Molecular classification
- Glycoprotein, Viral Surface Protein, Class I Fusion Protein
01
Overview
The hemagglutinin (HA) protein is a major surface glycoprotein of the Influenza A virus, specifically the H3N2 subtype. It is responsible for binding to host cell receptors via its HA1 subunit and mediating fusion between the viral envelope and host cell membrane (HA2 subunit), enabling viral entry. HA is a trimeric protein and the primary target for neutralizing antibodies, making it the key antigen in influenza vaccines. High variability due to antigenic drift necessitates frequent vaccine updates.
- Other names
- H3N2 HemagglutininHA protein (H3N2)Influenza A/H3N2 HemagglutininA/Hong Kong/1/1968 (H3N2) Hemagglutinin
02
Mechanism of action
Vaccines induce neutralizing antibodies that block HA-mediated receptor binding and membrane fusion. Monoclonal antibodies can directly neutralize the virus by binding to HA and preventing its function.
03
Biological functions
Receptor bindingMembrane fusionAntigen presentationViral entry
04
Disease associations
InfectionInfluenzaSeasonal Epidemics
05
Safety considerations
Antigenic drift (leading to vaccine mismatch)Potential for antibody-dependent enhancement (ADE) in some cases
06
Interacting drugs
Influenza vaccines
1 more in the full profile.
07
Biomarkers
HA antibody titer (for vaccine efficacy)HA sequence (for strain identification and vaccine matching)
Beyond the preview
Go deeper on Influenza A Virus Hemagglutinin Protein H3N2 Subtype (HA H3N2).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Influenza A Virus Hemagglutinin Protein H3N2 Subtype (HA H3N2).